Healx raises £37m in Series C funding to advance rare disease pipeline
The Series C round was co-led by R42 Group and Atomico to support clinical trials for rare disease treatments.
Healx is a clinical-stage biotechnology company that uses artificial intelligence to discover and develop treatments for rare diseases. Based in Cambridge, the organisation combines advanced drug discovery techniques with a growing clinical pipeline.
Healx has secured £37m in a Series C financing round to advance its clinical pipeline for rare diseases. The investment was co-led by R42 Group and Atomico, with participation from several new and existing backers including Balderton and Global Brain. The capital will primarily support the advancement of its lead drug candidate, HLX-1502, through an upcoming Phase 2 clinical trial for neurofibromatosis Type 1. Alongside the funding announcement, the company confirmed that the US Food and Drug Administration has cleared its investigational new drug application for the trial.
From the founder
"It is truly a pivotal time at Healx. By December 2024, we will advance HLX-1502 into a Phase 2 clinical trial in patients with NF1 both for plexiform neurofibroma, a genetic condition with limited treatment options and for cutaneous neurofibroma, for which there are no FDA approved options. We are also generating important preclinical data for multiple additional compounds identified using our novel generative AI drug discovery engine. Those compounds target rare diseases with significant unmet needs, including additional nerve-related tumor disorders, autosomal dominant polycystic kidney disease and neurodevelopmental disorders such as Angelman syndrome."
Tim Guilliams
CEO at Healx
Use of funds
- 01Continue product development
- 02Fund research and development
Investors
R42 Group
Atomico
Balderton
Jonathan Milner
Global Brain
btov
Ayana Capital
o2h
VU Venture Partners
Categories
About the company
Healx
Healx deploys artificial intelligence to discover new therapies for rare conditions.